Mitochondrially targeted vitamin E succinate efficiently kills breast tumour-initiating cells in a complex II-dependent manner
Bing Yan, Marina Stantic, Renata Zobalova, Ayenachew Bezawork-Geleta, Michael Stapelberg, Jan Stursa, Katerina Prokopova, Lanfeng Dong, Jiri Neuzil
BMC Cancer | BMC | Published : 2015
BACKGROUND: Accumulating evidence suggests that breast cancer involves tumour-initiating cells (TICs), which play a role in initiation, metastasis, therapeutic resistance and relapse of the disease. Emerging drugs that target TICs are becoming a focus of contemporary research. Mitocans, a group of compounds that induce apoptosis of cancer cells by destabilising their mitochondria, are showing their potential in killing TICs. In this project, we investigated mitochondrially targeted vitamin E succinate (MitoVES), a recently developed mitocan, for its in vitro and in vivo efficacy against TICs. METHODS: The mammosphere model of breast TICs was established by culturing murine NeuTL and human MC..View full abstract
Awarded by IGA
Awarded by BIOCEV European Regional Development Fund
This work was supported in part by funding from the National Health and Medical Research Council of Australia and Cancer Council Queensland to J.N. and L.F.D., and IGA (NT14078) to J.N., and by the BIOCEV European Regional Development Fund CZ.1.05/1.1.00/02.0109. B.Y. was supported by Griffith University International PhD Scholarship.